The impact of left ventricular systolic dysfunction on survival after renal transplantation

Andrew Siedlecki1, Margaret Foushee, John J Curtis

  • 1Division of Nephrology, Washington University, St. Louis, MO 63110, USA. asiedlec@im.wustl.edu

Transplantation
|January 1, 2008
PubMed

Insights

Reduced left ventricular ejection fraction (LVEF) before kidney transplant indicates higher risk for cardiac death and complications post-transplant, independent of coronary artery disease. This finding aids in risk stratification for renal transplant recipients.

Area of Science:

  • Cardiology
  • Nephrology
  • Transplantation Medicine

Background:

  • Gated single-photon emission computed tomography (SPECT) assesses myocardial perfusion and left ventricular ejection fraction (LVEF).
  • LVEF is a known risk factor for cardiac events in patients with coronary artery disease (CAD).
  • Pre-transplant cardiac risk assessment is crucial for renal allograft recipients.

Purpose of the Study:

  • To determine if decreased LVEF at the time of renal transplant evaluation is an independent risk factor for adverse cardiac outcomes after transplantation.
  • To investigate the association between pre-transplant left ventricular systolic dysfunction and post-transplant cardiac mortality and morbidity.

Main Methods:

  • Retrospective analysis of 653 renal allograft recipients who underwent stress SPECT imaging before transplantation (1998-2005).
  • Assessment of left ventricular systolic dysfunction defined as LVEF ≤45%.
  • Multivariate analysis to evaluate the independent impact of LV systolic dysfunction on post-transplant outcomes during a mean follow-up of 3.01 years.

Main Results:

  • 18% of patients (119/653) had left ventricular (LV) systolic dysfunction (LVEF ≤45%).
  • Patients with LV dysfunction had higher rates of cardiac complications (HR 1.8) and all-cause mortality (HR 2.0) post-transplant.
  • Multivariate analysis revealed LV systolic dysfunction was linked to a 5-fold increase in cardiac mortality, a 2-fold increase in all-cause mortality, and a 70% increase in cardiac complications.

Conclusions:

  • Pre-transplant systolic dysfunction is significantly associated with increased risks of overall and cardiac-related death after renal transplantation.
  • The association between systolic dysfunction and adverse outcomes is independent of underlying ischemic heart disease.
  • LVEF assessment via SPECT is a valuable tool for risk stratification in renal transplant candidates.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...